LAMC2
Basic information
Region (hg38): 1:183186238-183245127
Previous symbols: [ "EBR2", "LAMB2T", "LAMNB2", "EBR2A" ]
Links
Phenotypes
GenCC
Source:
- junctional epidermolysis bullosa (Definitive), mode of inheritance: AR
- junctional epidermolysis bullosa Herlitz type (Strong), mode of inheritance: AR
- junctional epidermolysis bullosa, non-Herlitz type (Strong), mode of inheritance: AR
- junctional epidermolysis bullosa Herlitz type (Strong), mode of inheritance: AR
- junctional epidermolysis bullosa, non-Herlitz type (Strong), mode of inheritance: AR
- generalized junctional epidermolysis bullosa non-Herlitz type (Supportive), mode of inheritance: AR
- junctional epidermolysis bullosa Herlitz type (Supportive), mode of inheritance: AR
- junctional epidermolysis bullosa Herlitz type (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Epidermolysis bullosa, junctional 3A, intermediate; Epidermolysis bullosa, junctional 3B, severe | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Dermatologic | 8012393; 11810295; 16473856; 21198797; 21801158 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (74 variants)
- Junctional epidermolysis bullosa (7 variants)
- Epidermolysis bullosa, junctional 3B, severe (4 variants)
- Junctional epidermolysis bullosa gravis of Herlitz (4 variants)
- Junctional epidermolysis bullosa, non-Herlitz type (3 variants)
- Epidermolysis bullosa, junctional 3A, intermediate (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the LAMC2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 430 | 441 | ||||
missense | 111 | 18 | 140 | |||
nonsense | 38 | 41 | 79 | |||
start loss | 2 | |||||
frameshift | 36 | 36 | 72 | |||
inframe indel | 6 | |||||
splice donor/acceptor (+/-2bp) | 37 | 43 | ||||
splice region | 1 | 4 | 68 | 1 | 74 | |
non coding | 37 | 149 | 63 | 249 | ||
Total | 82 | 115 | 156 | 598 | 81 |
Highest pathogenic variant AF is 0.00000657
Variants in LAMC2
This is a list of pathogenic ClinVar variants found in the LAMC2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-183186264-A-G | Junctional epidermolysis bullosa • Junctional epidermolysis bullosa, non-Herlitz type • Junctional epidermolysis bullosa gravis of Herlitz | Benign (Jul 08, 2021) | ||
1-183186274-G-A | Junctional epidermolysis bullosa | Uncertain significance (Jan 12, 2018) | ||
1-183186314-C-T | Junctional epidermolysis bullosa | Uncertain significance (Jan 13, 2018) | ||
1-183186315-C-G | Junctional epidermolysis bullosa | Benign (May 13, 2021) | ||
1-183186338-C-T | Junctional epidermolysis bullosa • Junctional epidermolysis bullosa gravis of Herlitz | Uncertain significance (Jan 12, 2018) | ||
1-183186347-C-A | Junctional epidermolysis bullosa • Junctional epidermolysis bullosa, non-Herlitz type • Junctional epidermolysis bullosa gravis of Herlitz | Benign (Jul 08, 2021) | ||
1-183186353-A-G | Junctional epidermolysis bullosa • Junctional epidermolysis bullosa gravis of Herlitz | Conflicting classifications of pathogenicity (Jan 13, 2018) | ||
1-183186354-T-C | Pathogenic (Mar 28, 2016) | |||
1-183186355-G-T | Junctional epidermolysis bullosa gravis of Herlitz | Likely pathogenic (Jan 11, 2017) | ||
1-183186358-T-C | Likely benign (Mar 03, 2022) | |||
1-183186361-G-C | Likely benign (Aug 16, 2023) | |||
1-183186361-G-T | Likely benign (Jan 29, 2024) | |||
1-183186366-G-A | Likely pathogenic (Dec 21, 2022) | |||
1-183186371-G-A | Inborn genetic diseases | Likely benign (Dec 15, 2023) | ||
1-183186373-C-G | Likely benign (Dec 26, 2023) | |||
1-183186373-C-T | Likely benign (Mar 05, 2022) | |||
1-183186382-C-G | Likely benign (Jul 17, 2023) | |||
1-183186382-C-T | Likely benign (Apr 14, 2022) | |||
1-183186388-C-T | Likely benign (Aug 16, 2023) | |||
1-183186391-G-C | Likely benign (Mar 01, 2023) | |||
1-183186391-G-T | Likely benign (Nov 06, 2023) | |||
1-183186394-C-G | Likely benign (Sep 10, 2023) | |||
1-183186400-G-C | Benign (Dec 30, 2023) | |||
1-183186400-G-T | Junctional epidermolysis bullosa | Conflicting classifications of pathogenicity (Jan 14, 2024) | ||
1-183186403-C-T | Likely benign (May 17, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
LAMC2 | protein_coding | protein_coding | ENST00000264144 | 23 | 58663 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.88e-12 | 1.00 | 125669 | 0 | 79 | 125748 | 0.000314 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.346 | 627 | 652 | 0.962 | 0.0000367 | 7819 |
Missense in Polyphen | 189 | 222.92 | 0.84783 | 2706 | ||
Synonymous | 0.611 | 234 | 246 | 0.951 | 0.0000138 | 2285 |
Loss of Function | 3.83 | 30 | 62.8 | 0.478 | 0.00000366 | 724 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000300 | 0.000300 |
Ashkenazi Jewish | 0.000199 | 0.000198 |
East Asian | 0.000489 | 0.000489 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000449 | 0.000448 |
Middle Eastern | 0.000489 | 0.000489 |
South Asian | 0.000262 | 0.000261 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components. Ladsin exerts cell- scattering activity toward a wide variety of cells, including epithelial, endothelial, and fibroblastic cells. {ECO:0000269|PubMed:8265624}.;
- Disease
- DISEASE: Epidermolysis bullosa, junctional, Herlitz type (H-JEB) [MIM:226700]: An infantile and lethal form of junctional epidermolysis bullosa, a group of blistering skin diseases characterized by tissue separation which occurs within the dermo- epidermal basement In the Herlitz type, death occurs usually within the first six months of life. Occasionally, children survive to teens. It is marked by bullous lesions at birth and extensive denudation of skin and mucous membranes that may be hemorrhagic. {ECO:0000269|PubMed:11810295, ECO:0000269|PubMed:8012393}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);ECM-receptor interaction - Homo sapiens (human);Focal adhesion - Homo sapiens (human);Small cell lung cancer - Homo sapiens (human);Amoebiasis - Homo sapiens (human);Toxoplasmosis - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Human papillomavirus infection - Homo sapiens (human);miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Alpha 6 Beta 4 signaling pathway;Focal Adhesion;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;PI3K-Akt Signaling Pathway;Inflammatory Response Pathway;Assembly of collagen fibrils and other multimeric structures;Signal Transduction;prion pathway;Alpha6Beta4Integrin;Laminin interactions;Collagen formation;Extracellular matrix organization;Anchoring fibril formation;Integrin;agrin in postsynaptic differentiation;Degradation of the extracellular matrix;a6b1 and a6b4 Integrin signaling;Non-integrin membrane-ECM interactions;MET activates PTK2 signaling;MET promotes cell motility;Signaling by MET;Type I hemidesmosome assembly;Cell junction organization;Signaling by Receptor Tyrosine Kinases;Cell-Cell communication;Beta1 integrin cell surface interactions;Alpha6 beta4 integrin-ligand interactions
(Consensus)
Recessive Scores
- pRec
- 0.413
Intolerance Scores
- loftool
- 0.774
- rvis_EVS
- 0.55
- rvis_percentile_EVS
- 81.39
Haploinsufficiency Scores
- pHI
- 0.0968
- hipred
- N
- hipred_score
- 0.372
- ghis
- 0.448
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.352
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Lamc2
- Phenotype
- growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); cellular phenotype; limbs/digits/tail phenotype; craniofacial phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; renal/urinary system phenotype; skeleton phenotype; digestive/alimentary phenotype; hearing/vestibular/ear phenotype;
Gene ontology
- Biological process
- cell adhesion;positive regulation of cell population proliferation;epidermis development;extracellular matrix organization;positive regulation of cell migration;hemidesmosome assembly;system development;basement membrane assembly
- Cellular component
- extracellular region;laminin-2 complex;extracellular space;cell cortex;membrane;perinuclear region of cytoplasm;collagen-containing extracellular matrix
- Molecular function
- extracellular matrix structural constituent;heparin binding